drugset / Trial / NCT02807987

Study of CS-3150 in Combination With ARB or ACE Inhibitor in Hypertensive Patients With Moderate Renal Impairment

NCT02807987

Phase 3 Completed 58 enrolled Daiichi Sankyo
NaSingle-groupOpen-labelTreatment

Summary

To examine antihypertensive effect and safety of administration of CS-3150 in combination with ARB or ACE inhibitor in hypertensive patients with moderate renal impairment.

Timeline

Start
2016-06
Primary completion
2017-05-15
Completion
2017-05-15

Drugs

EvaluationDrugModalityDoseRoute
Subject CS-3150 Unknown 1.25 mg Oral
Subject CS-3150 Unknown 2.5 mg Oral
Subject CS-3150 Unknown 5 mg Oral

Indications